Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | PDE2A | O00408 | 9/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23728526 | 0.87 | ALDH1A1 (0.56) | KDM4ERAB9ANPC1ALDH1A1HPGD | |
| SCHEMBL23728550 | 0.87 | ALDH1A1 (0.56) | KDM4ERAB9ANPC1ALDH1A1HPGD | |
| SCHEMBL23728472 | 0.86 | ALDH1A1 (0.55) | KDM4ERAB9ANPC1ALDH1A1HPGD | |
| SCHEMBL14033767 | 0.86 | ALDH1A1 (0.55) | KDM4ERAB9ANPC1ALDH1A1HPGD | |
| SCHEMBL309140 | 0.86 | ALDH1A1 (0.55) | KDM4ERAB9ANPC1ALDH1A1HPGD | |
| SCHEMBL19045790 | 0.85 | PDE2A (0.57) | KDM4ERAB9ANPC1ALDH1A1HPGD | |
| SCHEMBL23728470 | 0.85 | ALDH1A1 (0.54) | KDM4ERAB9ANPC1ALDH1A1HPGD | |
| SCHEMBL23728603 | 0.83 | KDM4E (0.55) | KDM4ERAB9ANPC1ALDH1A1HPGD | |
| SCHEMBL14033079 | 0.83 | ALDH1A1 (0.53) | KDM4ERAB9ANPC1ALDH1A1HPGD | |
| SCHEMBL23728467 | 0.83 | ALDH1A1 (0.53) | KDM4ERAB9ANPC1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286993-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | BOEHRINGER INGELHEIM INT (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230286993-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | BOEHRINGER INGELHEIM INT (DE) | 2023-09-14 | — | — | US | disclosed |
| US-11691977-B2 | Cyclic ether derivatives of pyrazolo[1,5-A]pyrimidine-3-carboxyamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-07-04 | — | — | US | disclosed |
| US-11691977-B2 | Cyclic ether derivatives of pyrazolo[1,5-A]pyrimidine-3-carboxyamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-07-04 | — | — | US | disclosed |
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| EP-4100004-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158634-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021158634-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-20210032259-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | BOEHRINGER INGELHEIM INT (DE) | 2021-02-04 | — | — | US | disclosed |
| US-10023575-B2 | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-07-17 | — | — | US | disclosed |
| US-10023575-B2 | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-07-17 | — | — | US | disclosed |
| US-20180134720-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | BOEHRINGER INGELHEIM INT (DE) | 2018-05-17 | — | — | US | disclosed |
| US-20180134720-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | BOEHRINGER INGELHEIM INT (DE) | 2018-05-17 | — | — | US | disclosed |
| WO-2017064082-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-04-20 | — | — | WO | disclosed |
| EP-3156405-A1 | SPIROCYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE | Boehringer Ingelheim International GmbH (DE) | 2017-04-19 | — | — | EP | disclosed |
| US-20170101411-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-04-13 | — | — | US | disclosed |
| US-20170101411-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-04-13 | — | — | US | disclosed |
| US-20160159808-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3026051-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134720-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | CNP, PDE5A, PDE3A | KDM4E 458/4885RAB9A 3007/4885NPC1 2029/4885 |
| US-20230286993-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | CNP, PDE3A, PDE5A | KDM4E 431/4885RAB9A 2691/4885NPC1 2813/4885 |
| US-20170101411-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | CNP, PDE5A, PDE3A | KDM4E 458/4885RAB9A 3007/4885NPC1 2029/4885 |
| US-20210032259-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | CNP, PDE5A, PDE3A | KDM4E 458/4885RAB9A 3007/4885NPC1 2029/4885 |
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885RAB9A 4270/4885NPC1 3159/4885 |
| US-11691977-B2 | Cyclic ether derivatives of pyrazolo[1,5-A]pyrimidine-3-carboxyamide | CNP, PDE5A, PDE3A | KDM4E 458/4885RAB9A 3007/4885NPC1 2029/4885 |
| US-20160159808-A1 | HETEROCYCLIC COMPOUND | PDE2A, PDE3A, PDE5A | KDM4E 1323/4885RAB9A 159/4885NPC1 2045/4885 |
| US-10023575-B2 | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide | CNP, PDE5A, PDE3A | KDM4E 458/4885RAB9A 3007/4885NPC1 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.